Stockreport

Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer

PROVECTUS BIOPHARMS  (PVCT) 
NASDAQ:AMEX Investor Relations: provectusbio.com/financial-overview
PDF KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a pre [Read more]